COCH

SEC source: 0001062993-25-010396 · form4.xml · nonDerivative · entry 2

BRYNELSEN CHARLES · CIK 0001712459 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6333 to $1.6497 inclusive. The reporting person undertakes to provide Envoy Medical, Inc., any security holder of Envoy Medical, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001062993-25-010396 · form4.xml · nonDerivative · entry 1

BRYNELSEN CHARLES · CIK 0001712459 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6875 to $1.6794 inclusive. The reporting person undertakes to provide Envoy Medical, Inc., any security holder of Envoy Medical, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001062993-25-005363 · form4.xml · derivative · entry 10

TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · GAT Funding, LLC

Disclosed balance after: 750,000

Underlying: Class A Common Stock · 750,000 shares

Expires 2028-03-11

F4 · kind: In connection with the promissory note issuance effective March 6, 2025 and the closing of the initial funding on March 11, 2025, this warrant was issued to GAT Funding, LLC, as described in more detail in Item 1.01 of the Issuer's 8-K as filed with the SEC on March 12, 2025.

F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person.

SEC source: 0001140361-24-050422 · form4.xml · nonDerivative · entry 1

Kantor Susan · CIK 0001673071 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,887

F1 · kind: These shares were received by the reporting person in connection with a pro-rata distribution in-kind by Anzu SPAC GP I LLC to its members for no consideration.

SEC source: 0001140361-24-050420 · form4.xml · nonDerivative · entry 2

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · kind: Represents a pro-rata distribution in-kind by the Sponsor to its members for no consideration.

F2 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

SEC source: 0001140361-24-050420 · form4.xml · nonDerivative · entry 1

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,028,986

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On December 20, 2024, Anzu SPAC GP I LLC (the "Sponsor") converted 373,333 shares of Series A Preferred Stock, par value $0.0001 ("Preferred Stock") of Envoy Medical, Inc. (the "Issuer") into 1,028,986 shares of Class A Common Stock, par value $0.0001 per share ("Common Stock") pursuant to the terms set forth in the Certificate of Designation for the Preferred Stock (the "Certificate of Designation").

F2 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-020597 · form4.xml · derivative · entry 5

Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,987

Underlying: Class A Common Stock · 16,694 shares

Expires 2028-09-29

F3 · derivative.exercise_date: Fully exercisable.

SEC source: 0001062993-24-020597 · form4.xml · derivative · entry 4

Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,293

Underlying: Class A Common Stock · 94,293 shares

Expires 2028-09-29

F3 · derivative.exercise_date: Fully exercisable.

SEC source: 0001062993-24-020770 · form4.xml · derivative · entry 9

TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · GAT Funding, LLC

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2026-08-27

F4 · kind: In connection with the Issuer's draw under the promissory note issued on August 27, 2024 to GAT Funding, LLC, this warrant was issued as a commitment fee, as described in more detail in Item 1.01 of the Issuer's 8-K as filed with the SEC on December 17, 2024.

F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person.

SEC source: 0001062993-25-011296 · form4.xml · nonDerivative · entry 1

Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,743

F1 · kind: These shares were acquired under the Envoy Medical, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001062993-24-019574 · form4.xml · nonDerivative · entry 1

Patel Mona Chetan · CIK 0001995769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

SEC source: 0001062993-24-019530 · form4.xml · nonDerivative · entry 1

Kantor Susan · CIK 0001673071 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,182

F1 · kind: These shares were received by the reporting person in connection with a pro-rata distribution in-kind by Anzu SPAC GP I LLC to its members for no consideration.

SEC source: 0001062993-24-019529 · form4.xml · nonDerivative · entry 1

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

F1 · kind: Represents a pro-rata distribution in-kind by Anzu SPAC GP I LLC (the "Sponsor") to its members for no consideration.

F2 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-24-016486 · form4.xml · nonDerivative · entry 2

Patel Mona Chetan · CIK 0001995769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: Represents a weighted average price. These shares of Class A Common Stock were purchased in multiple transactions at prices ranging from $3.28 to $3.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

SEC source: 0001062993-24-016486 · form4.xml · nonDerivative · entry 1

Patel Mona Chetan · CIK 0001995769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000

SEC source: 0001062993-24-015872 · form4.xml · derivative · entry 8

TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · GAT Funding, LLC

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2026-08-27

F4 · kind: In connection with the Issuer's draw under the promissory note issued on August 27, 2024 to GAT Funding, LLC, this warrant was issued as a commitment fee, as described in more detail in Item 1.01 of the Issuer's 8-K as filed with the SEC on August 28, 2024.

F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person.

SEC source: 0001062993-24-014844 · form4.xml · derivative · entry 1

Crowe Michael Curtis · CIK 0002026683 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2034-08-08

F1 · derivative.exercise_date: Options to purchase 6,250 shares vest on 08/08/2025, and the remaining 18,750 shares vest pro rata on the 8th of each month thereafter for 36 consecutive months.

SEC source: 0001062993-24-014054 · form4.xml · derivative · entry 7

TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · GAT Funding, LLC

Disclosed balance after: 250,000

Underlying: Class A Common Stock · 250,000 shares

Expires 2026-02-27

F4 · kind: In connection with the Issuer's draw under the promissory note issued in February 2024 to GAT Funding, LLC, this warrant was issued as a commitment fee, as described in more detail in Exhibit 10.1 of the Issuer's 10-Q as filed with the SEC on May 15, 2024.

F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person.

SEC source: 0001062993-24-013065 · form4.xml · nonDerivative · entry 2

Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by Family Education Trust

Disclosed balance after: 12,720

F1 · shares: Pro rata distribution from Cornerstone Growth Group, LP and Cornerstone Growth Group II, LP, of which the reporting person was a non-managing member and did not have voting, dispositive or other rights.

SEC source: 0001062993-24-013065 · form4.xml · nonDerivative · entry 1

Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,615

F1 · shares: Pro rata distribution from Cornerstone Growth Group, LP and Cornerstone Growth Group II, LP, of which the reporting person was a non-managing member and did not have voting, dispositive or other rights.

SEC source: 0001062993-24-011337 · form4.xml · derivative · entry 6

TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · GAT Funding, LLC

Disclosed balance after: 250,000

Underlying: Class A Common Stock · 250,000 shares

Expires 2026-02-27

F4 · kind: In connection with the Issuer's draw under the promissory note issued in February 2024 to GAT Funding, LLC, this warrant was issued as a commitment fee, as described in more detail under Item 1.01 in the Issuer's 8-K as filed with the SEC on May 24, 2024.

F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person.

SEC source: 0001062993-24-005235 · form4.xml · derivative · entry 5

TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · GAT Funding LLC

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2026-02-26

F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person.

SEC source: 0001140361-24-050420 · form4.xml · derivative · entry 3

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,126,667

Underlying: Class A Common Stock, par value $0.0001 per share · 1,028,986 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: As disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on December 20, 2024, pursuant to the Conversion and Waiver Agreement between the Issuer and the Sponsor, among other things, the Issuer made a voluntary, temporary reduction in the conversion price, pursuant to the terms of the Certificate of Designation, of all of the outstanding shares of Preferred Stock effective December 20, 2024 through January 20, 2025 from $11.50 per share of Common Stock issuable upon conversion of a share of Preferred Stock to $3.63, with the conversion ratio determined by dividing the $10.00 original issue price of the Preferred Stock by such conversion price.

F1 · shares: On December 20, 2024, Anzu SPAC GP I LLC (the "Sponsor") converted 373,333 shares of Series A Preferred Stock, par value $0.0001 ("Preferred Stock") of Envoy Medical, Inc. (the "Issuer") into 1,028,986 shares of Class A Common Stock, par value $0.0001 per share ("Common Stock") pursuant to the terms set forth in the Certificate of Designation for the Preferred Stock (the "Certificate of Designation").

F5 · price: The shares of Preferred Stock have no expiration date. The shares of Preferred Stock are subject to mandatory conversion into shares of Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Preferred Stock to shares of Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F5 · derivative.exercise_date: The shares of Preferred Stock have no expiration date. The shares of Preferred Stock are subject to mandatory conversion into shares of Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Preferred Stock to shares of Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F5 · derivative.expiration_date: The shares of Preferred Stock have no expiration date. The shares of Preferred Stock are subject to mandatory conversion into shares of Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Preferred Stock to shares of Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F1 · derivative.underlying_shares: On December 20, 2024, Anzu SPAC GP I LLC (the "Sponsor") converted 373,333 shares of Series A Preferred Stock, par value $0.0001 ("Preferred Stock") of Envoy Medical, Inc. (the "Issuer") into 1,028,986 shares of Class A Common Stock, par value $0.0001 per share ("Common Stock") pursuant to the terms set forth in the Certificate of Designation for the Preferred Stock (the "Certificate of Designation").

F2 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-23-021438 · form4.xml · nonDerivative · entry 2

Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,831

SEC source: 0001062993-23-021438 · form4.xml · nonDerivative · entry 1

Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,451

SEC source: 0001062993-23-021360 · form4.xml · derivative · entry 4

TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · GAT Funding LLC

Disclosed balance after: 1,100,000

Underlying: Class A Common Stock · 956,522 shares

Expires not disclosed

F3 · derivative.exercise_date: Fully exercisable and there is no expiration date.

F3 · derivative.expiration_date: Fully exercisable and there is no expiration date.

F4 · derivative.underlying_shares: The original filing on October 3, 2023 contained a calculation error and the amount shown in column 7 now reflects the correct number of shares issuable upon conversion.

F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person.

SEC source: 0001062993-23-021838 · form4a.xml · derivative · entry 4

TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · GAT Funding LLC

Disclosed balance after: 1,000,000

Underlying: Class A Common Stock · 869,565 shares

Expires not disclosed

F3 · kind: This Amendment reports the cancellation of the purchase of 100,000 shares of Series A Preferred Stock on November 20, 2023 by GAT Funding, LLC ("GAT"), which was reported in the original Form 4. The purchase of the reported Series A Preferred Stock was cancelled due to a determination that certain conditions precedent to the purchase of the Series A Preferred Stock in the agreement had not been met.

F3 · shares: This Amendment reports the cancellation of the purchase of 100,000 shares of Series A Preferred Stock on November 20, 2023 by GAT Funding, LLC ("GAT"), which was reported in the original Form 4. The purchase of the reported Series A Preferred Stock was cancelled due to a determination that certain conditions precedent to the purchase of the Series A Preferred Stock in the agreement had not been met.

F4 · derivative.exercise_date: Fully exercisable and there is no expiration date.

F4 · derivative.expiration_date: Fully exercisable and there is no expiration date.

F3 · derivative.underlying_shares: This Amendment reports the cancellation of the purchase of 100,000 shares of Series A Preferred Stock on November 20, 2023 by GAT Funding, LLC ("GAT"), which was reported in the original Form 4. The purchase of the reported Series A Preferred Stock was cancelled due to a determination that certain conditions precedent to the purchase of the Series A Preferred Stock in the agreement had not been met.

F3 · balance_after: This Amendment reports the cancellation of the purchase of 100,000 shares of Series A Preferred Stock on November 20, 2023 by GAT Funding, LLC ("GAT"), which was reported in the original Form 4. The purchase of the reported Series A Preferred Stock was cancelled due to a determination that certain conditions precedent to the purchase of the Series A Preferred Stock in the agreement had not been met.

F2 · ownership.nature: GAT Funding, LLC is an entity controlled by the Reporting Person.

SEC source: 0001062993-23-019481 · form4.xml · derivative · entry 2

Kantor Susan · CIK 0001673071 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Class A Common Stock · 62,500 shares

Expires 2033-10-15

F1 · price: Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

F1 · derivative.exercise_date: Options to purchase 15,625 shares vest on 10/15/2024, and the remaining 46,875 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

SEC source: 0001062993-23-019440 · form4.xml · derivative · entry 1

Wells David R. · CIK 0001480371 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 293,250

Underlying: Class A Common Stock · 293,250 shares

Expires 2033-10-15

F1 · derivative.exercise_date: Options to purchase 73,313 shares vest on 10/15/2024, and the remaining 219,937 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

SEC source: 0001062993-23-019448 · form4.xml · derivative · entry 1

BRYNELSEN CHARLES · CIK 0001712459 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Class A Common Stock · 62,500 shares

Expires 2033-10-15

F1 · derivative.exercise_date: Options to purchase 46,875 shares vest on 10/15/2023, and the remaining 15,625 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

SEC source: 0001062993-23-019479 · form4.xml · derivative · entry 5

Lucas Brent T. · CIK 0001994382 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 879,749

Underlying: Class A Common Stock · 879,749 shares

Expires 2033-10-15

F1 · derivative.exercise_date: Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

SEC source: 0001062993-23-019443 · form4.xml · derivative · entry 1

Patel Mona Chetan · CIK 0001995769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2033-10-15

F1 · derivative.exercise_date: Options to purchase 6,250 shares vest on 10/15/2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

SEC source: 0001062993-23-019436 · form4.xml · derivative · entry 1

Smith-Gomez Janis · CIK 0001995670 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2033-10-15

F1 · derivative.exercise_date: Options to purchase 6,250 shares vest on 10/15/2024, and the remaining 18,750 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

SEC source: 0001062993-23-018935 · form4.xml · derivative · entry 2

Kantor Susan · CIK 0001673071 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock, par value $0.0001 per share · 25,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share.

F1 · kind: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share.

F1 · price: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share.

F1 · derivative.exercise_date: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share.

F1 · derivative.expiration_date: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share.

F1 · balance_after: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share.

SEC source: 0001062993-23-018935 · form4.xml · nonDerivative · entry 1

Kantor Susan · CIK 0001673071 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 29, 2023, in connection with the consummation of the business combination between Anzu Special Acquisition Corp I and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share.

SEC source: 0001062993-23-018934 · form4.xml · derivative · entry 2

Hirsch Daniel J. · CIK 0001453077 · Director · CFO and Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock, par value $0.0001 per share · 25,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Mr. Hirsch resigned as Chief Financial Officer, Corporate Secretary, and Director of Anzu.

F1 · kind: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Mr. Hirsch resigned as Chief Financial Officer, Corporate Secretary, and Director of Anzu.

F1 · price: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Mr. Hirsch resigned as Chief Financial Officer, Corporate Secretary, and Director of Anzu.

F1 · derivative.exercise_date: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Mr. Hirsch resigned as Chief Financial Officer, Corporate Secretary, and Director of Anzu.

F1 · derivative.expiration_date: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Mr. Hirsch resigned as Chief Financial Officer, Corporate Secretary, and Director of Anzu.

SEC source: 0001062993-23-018934 · form4.xml · nonDerivative · entry 1

Hirsch Daniel J. · CIK 0001453077 · Director · CFO and Corporate Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Mr. Hirsch resigned as Chief Financial Officer, Corporate Secretary, and Director of Anzu.

F1 · price: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Mr. Hirsch resigned as Chief Financial Officer, Corporate Secretary, and Director of Anzu.

SEC source: 0001062993-23-018936 · form4.xml · derivative · entry 2

Huskins Priya Cherian · CIK 0001419882 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock, par value $0.0001 per share · 25,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Huskins resigned as a director of Anzu.

F1 · kind: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Huskins resigned as a director of Anzu.

F1 · price: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Huskins resigned as a director of Anzu.

F1 · derivative.exercise_date: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Huskins resigned as a director of Anzu.

F1 · derivative.expiration_date: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Huskins resigned as a director of Anzu.

SEC source: 0001062993-23-018936 · form4.xml · nonDerivative · entry 1

Huskins Priya Cherian · CIK 0001419882 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Huskins resigned as a director of Anzu.

F1 · price: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Huskins resigned as a director of Anzu.

SEC source: 0001062993-23-018933 · form4.xml · derivative · entry 2

DEWBREY DIANE L · CIK 0001200125 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock, par value $0.0001 per share · 25,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Dewbrey resigned as a director of Anzu.

F1 · kind: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Dewbrey resigned as a director of Anzu.

F1 · price: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Dewbrey resigned as a director of Anzu.

F1 · derivative.exercise_date: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Dewbrey resigned as a director of Anzu.

F1 · derivative.expiration_date: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Dewbrey resigned as a director of Anzu.

SEC source: 0001062993-23-018933 · form4.xml · nonDerivative · entry 1

DEWBREY DIANE L · CIK 0001200125 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Dewbrey resigned as a director of Anzu.

F1 · price: On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Dewbrey resigned as a director of Anzu.

SEC source: 0001062993-23-018900 · form4.xml · derivative · entry 5

TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 869,565

Underlying: Class A Common Stock · 869,565 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents the conversion of Reporting Person's $10,000,000 Envoy Bridge Note into shares of Series A Preferred Stock at $10 per share.

F4 · derivative.exercise_date: Fully exercisable and there is no expiration date.

F4 · derivative.expiration_date: Fully exercisable and there is no expiration date.

SEC source: 0001062993-23-018900 · form4.xml · derivative · entry 4

TAYLOR GLEN A · CIK 0001213971 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Series A Preferred Stock · 1,000,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Represents the conversion of Reporting Person's $10,000,000 Envoy Bridge Note into shares of Series A Preferred Stock at $10 per share.

F4 · derivative.exercise_date: Fully exercisable and there is no expiration date.

F4 · derivative.expiration_date: Fully exercisable and there is no expiration date.

SEC source: 0001062993-23-018937 · form4.xml · derivative · entry 7

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock, par value $0.0001 per share · 2,490,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_price: On September 29, 2023, in connection with the Closing, each share of Class B Common Stock automatically converted into one share of Class A Common Stock.

F10 · shares: On September 29, 2023, in connection with the Closing, each share of Class B Common Stock automatically converted into one share of Class A Common Stock.

F10 · price: On September 29, 2023, in connection with the Closing, each share of Class B Common Stock automatically converted into one share of Class A Common Stock.

F10 · derivative.exercise_date: On September 29, 2023, in connection with the Closing, each share of Class B Common Stock automatically converted into one share of Class A Common Stock.

F10 · derivative.expiration_date: On September 29, 2023, in connection with the Closing, each share of Class B Common Stock automatically converted into one share of Class A Common Stock.

F3 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-23-018937 · form4.xml · derivative · entry 6

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,490,000

Underlying: Class A Common Stock, par value $0.001 per share · 2,500,000 shares

Expires not disclosed

F8 · derivative.exercise_price: On September 29, 2023, in connection with the Closing, an aggregate of 2,500,000 shares of Series A Preferred Stock were issued to the Sponsor in exchange for 2,500,000 shares of Class B Common Stock held by the Sponsor in a private exchange offer.

F8 · shares: On September 29, 2023, in connection with the Closing, an aggregate of 2,500,000 shares of Series A Preferred Stock were issued to the Sponsor in exchange for 2,500,000 shares of Class B Common Stock held by the Sponsor in a private exchange offer.

F8 · price: On September 29, 2023, in connection with the Closing, an aggregate of 2,500,000 shares of Series A Preferred Stock were issued to the Sponsor in exchange for 2,500,000 shares of Class B Common Stock held by the Sponsor in a private exchange offer.

F8 · derivative.exercise_date: On September 29, 2023, in connection with the Closing, an aggregate of 2,500,000 shares of Series A Preferred Stock were issued to the Sponsor in exchange for 2,500,000 shares of Class B Common Stock held by the Sponsor in a private exchange offer.

F8 · derivative.expiration_date: On September 29, 2023, in connection with the Closing, an aggregate of 2,500,000 shares of Series A Preferred Stock were issued to the Sponsor in exchange for 2,500,000 shares of Class B Common Stock held by the Sponsor in a private exchange offer.

F3 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-23-018937 · form4.xml · derivative · entry 5

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,990,000

Underlying: Class A Common Stock, par value $0.0001 per share · 5,510,000 shares

Expires not disclosed

F9 · derivative.exercise_price: On September 29, 2023, in connection with the Closing, the Sponsor forfeited 5,510,000 shares of Class B Common Stock.

F9 · shares: On September 29, 2023, in connection with the Closing, the Sponsor forfeited 5,510,000 shares of Class B Common Stock.

F9 · price: On September 29, 2023, in connection with the Closing, the Sponsor forfeited 5,510,000 shares of Class B Common Stock.

F9 · derivative.exercise_date: On September 29, 2023, in connection with the Closing, the Sponsor forfeited 5,510,000 shares of Class B Common Stock.

F9 · derivative.expiration_date: On September 29, 2023, in connection with the Closing, the Sponsor forfeited 5,510,000 shares of Class B Common Stock.

F3 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-23-018937 · form4.xml · derivative · entry 4

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Class A Common Stock, par value $0.0001 per share · 2,173,913 shares

Expires not disclosed

F6 · derivative.exercise_price: These shares of Series A Preferred Stock have no expiration date. These shares of Series A Preferred Stock are subject to mandatory conversion into shares of Class A Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Series A Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Series A Preferred Stock to shares of Class A Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Class A Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F8 · shares: On September 29, 2023, in connection with the Closing, an aggregate of 2,500,000 shares of Series A Preferred Stock were issued to the Sponsor in exchange for 2,500,000 shares of Class B Common Stock held by the Sponsor in a private exchange offer.

F8 · price: On September 29, 2023, in connection with the Closing, an aggregate of 2,500,000 shares of Series A Preferred Stock were issued to the Sponsor in exchange for 2,500,000 shares of Class B Common Stock held by the Sponsor in a private exchange offer.

F6 · derivative.exercise_date: These shares of Series A Preferred Stock have no expiration date. These shares of Series A Preferred Stock are subject to mandatory conversion into shares of Class A Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Series A Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Series A Preferred Stock to shares of Class A Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Class A Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F6 · derivative.expiration_date: These shares of Series A Preferred Stock have no expiration date. These shares of Series A Preferred Stock are subject to mandatory conversion into shares of Class A Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Series A Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Series A Preferred Stock to shares of Class A Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Class A Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F6 · derivative.underlying_shares: These shares of Series A Preferred Stock have no expiration date. These shares of Series A Preferred Stock are subject to mandatory conversion into shares of Class A Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Series A Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Series A Preferred Stock to shares of Class A Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Class A Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F3 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-23-018937 · form4.xml · derivative · entry 3

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote 6

Disclosed balance after: 1,000,000

Underlying: Class A Common Stock, par value $0.0001 per share · 869,565 shares

Expires not disclosed

F6 · derivative.exercise_price: These shares of Series A Preferred Stock have no expiration date. These shares of Series A Preferred Stock are subject to mandatory conversion into shares of Class A Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Series A Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Series A Preferred Stock to shares of Class A Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Class A Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F7 · shares: On April 17, 2023, the Issuer entered into a subscription agreement with the Sponsor pursuant to which AICP III L.P., Anzu Industrial Capital Partners III, L.P. and Anzu Industrial Capital Partners III QP, L.P., each an affiliate of the Sponsor, paid an aggregate $10,000,000 in exchange for 1,000,000 shares of Series A preferred stock, par value $0.0001 per share ("Series A Preferred Stock"), which shares were issued to such affiliates on September 29, 2023.

F6 · derivative.exercise_date: These shares of Series A Preferred Stock have no expiration date. These shares of Series A Preferred Stock are subject to mandatory conversion into shares of Class A Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Series A Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Series A Preferred Stock to shares of Class A Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Class A Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F6 · derivative.expiration_date: These shares of Series A Preferred Stock have no expiration date. These shares of Series A Preferred Stock are subject to mandatory conversion into shares of Class A Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Series A Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Series A Preferred Stock to shares of Class A Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Class A Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F6 · derivative.underlying_shares: These shares of Series A Preferred Stock have no expiration date. These shares of Series A Preferred Stock are subject to mandatory conversion into shares of Class A Common Stock at the Issuer's sole discretion upon the occurrence of certain events specified in the Certificate of Designation. In addition, holders of Series A Preferred Stock have the right, at any time at such preferred stockholder's option, to convert each share of Series A Preferred Stock to shares of Class A Common Stock based on the ratio determined by dividing the Original Issuance Price of $10.00 per share by the Conversion Price of $11.50 per share, subject to certain customary adjustments in the event of certain events affecting the price of the Class A Common Stock, such as stock splits and combinations, or the distribution of options, rights or warrants, as described in the Certificate of Designation.

F3 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-23-018937 · form4.xml · nonDerivative · entry 2

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000,000

F4 · price: The Sponsor transferred an aggregate of 490,000 shares of Class A Common Stock to various third parties pursuant to (i) the extension support agreements between the Issuer, the Sponsor and several unaffiliated third parties and (ii) the side letter agreements between the Sponsor and certain institutional investors.

F5 · balance_after: 1,000,000 of these shares have vested. The remaining 1,000,000 shares remain unvested and subject to forfeiture, and will vest upon the U.S. Food and Drug Administration's approval of the Issuer's Acclaim cochlear implant device or upon a change of control of the Issuer. All 2,000,000 shares are subject to a contractual lock-up agreement and may only be transferred in accordance with the terms thereof.

F3 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.

SEC source: 0001062993-23-018937 · form4.xml · nonDerivative · entry 1

Anzu SPAC GP I LLC · CIK 0001846378 · 10% owner

Haring-Smith Whitney · CIK 0001846535 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,490,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares were issued in connection with the automatic conversion of an equal number of shares of Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), which converted to Class A Common Stock, par value $0.0001 per share ("Class A Common Stock"), upon the closing (the "Closing") of the business combination between Anzu Special Acquisition Corp. I and Envoy Medical Corporation (the "Business Combination").... (continued)

F2 · price: (Continued from footnote 1) ...Prior to the Closing, Anzu SPAC GP I LLC (the "Sponsor") beneficially owned 10,500,000 shares of Class B Common Stock. In connection with the Closing, the Sponsor forfeited 5,510,000 shares of Class B Common Stock and exchanged 2,500,000 shares of Class B Common Stock for an equal number of shares of Series A Preferred Stock, par value $0.0001 ("Series A Preferred Stock") in a private exchange offer. The Issuer's remaining 2,490,000 shares of Class B Common Stock automatically converted to an equal number of shares of Class A Common Stock upon the Closing.

F3 · ownership.direct: Dr. Whitney Haring-Smith shares voting and investment control over shares held by the Sponsor, and, as a result, may be deemed to beneficially own the securities reported herein. Dr. Haring-Smith disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.